Trial Profile
NATIONAL, MULTICENTER, RANDOMIZED,OPEN STUDY TO EVALUATE EFFICACY AND SAFETY OF LAMIVUDINE (300 MG QD) MONOTHERAPY AS AN ALTERNATIVE TO THERAPEUTIC INTERRUPTION IN PAZIENTS AFFECTED BY HIV-1, IN VIRAL FAILURE, WITH M184V MUTATION.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2011
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2011 New trial record